Human CellExp™ VLDLR, human recombinant

VLDLR

The very-low-density-lipoprotein receptor (VLDL-R) is a lipoprotein receptor that shows considerable similarity to the low density-lipoprotein receptor. VLDL R is a 130 kDa type I transmembrane protein in the LDL receptor family that plays a significant role in lipid metabolism and in nervous system development and function .This receptor has been suggested to be important for the metabolism of apoprotein-E-containing triacylglycerol-rich lipoproteins, such as very-low-density lipoprotein (VLDL), beta-migrating VLDL and intermediate-density lipoprotein. It is also one of the receptors of reelin, an extracellular matrix protein which regulates the processes of neuronal migration and synaptic plasticity. In humans, the VLDL-R is encoded by the VLDLR gene. A rare neurological disorder first described in the 1970s under the name "disequilibrium syndrome" is now considered to be caused by the disruption of VLDLR gene. The disorder was renamed VLDLR-associated cerebellar hypoplasia (VLDLRCH) after a 2005 study. It is associated with parental consanguinity and found in secluded communities such as the Hutterites. VLDLRCH is one of the two known genetic disorders caused by a disruption of reelin signaling pathway, along with Norman-Roberts syndrome.

N/A

This protein comprises 781 amino acids with polyhistidine tag at C-terminus and has a calculated MW of 86 kDa. The predicted N-terminus is Gly 28. DTT-reduced protein migrates as 150 & 180 kDa polypeptide in SDS-PAGE due to different glycosylation.

VLDLR, CARMQ1, CHRMQ1, FLJ35024, VLDLRCH, VLDL-R, very-low-density-lipoprotein receptor

VLDLR, CARMQ1, CHRMQ1, FLJ35024, VLDLRCH, VLDL-R, very-low-density-lipoprotein receptor

7436

VLDLR

Human

P98155

Yes

HEK293 cells

≥97%

SDS-PAGE, N/A

N/A

Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein E3 is immobilized at 1 μg/ml (100 μl/well), the concentration of Recombinant Human VLDLR that produces 50% of the optimal binding response is found to be approximately 0.03 - 0.15 μg/ml.

Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein E3 is immobilized at 1 μg/ml (100 μl/well), the concentration of Recombinant Human VLDLR that produces 50% of the optimal binding response is found to be approximately 0.03 - 0.15 μg/ml.

N/A

N/A

-20°C

Gel Pack

Lyophilized

Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.

Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.

N/A

Centrifuge the vial prior to opening.

For Research Use Only! Not to be used in humans

Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.

Recombinants or rec. proteins

recombinants